Little House Capital LLC Takes Position in ResMed Inc. (NYSE:RMD)

Little House Capital LLC bought a new stake in ResMed Inc. (NYSE:RMD - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,299 shares of the medical equipment provider's stock, valued at approximately $739,000.

Other hedge funds also recently added to or reduced their stakes in the company. Global X Japan Co. Ltd. lifted its stake in ResMed by 121.4% in the first quarter. Global X Japan Co. Ltd. now owns 124 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 68 shares during the last quarter. Colonial Trust Co SC raised its stake in shares of ResMed by 6,250.0% during the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of ResMed during the fourth quarter valued at about $33,000. Golden State Wealth Management LLC raised its stake in shares of ResMed by 384.8% during the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 127 shares in the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in shares of ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 150 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RMD has been the topic of a number of recent analyst reports. Royal Bank Of Canada lifted their price objective on shares of ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a research note on Thursday, April 24th. KeyCorp set a $274.00 price objective on shares of ResMed in a research note on Thursday, April 24th. Citigroup upgraded shares of ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Morgan Stanley set a $286.00 price objective on shares of ResMed and gave the company an "overweight" rating in a research note on Tuesday, May 20th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $259.33.

ResMed Price Performance

NYSE:RMD traded down $1.19 during mid-day trading on Friday, reaching $255.02. 1,498,338 shares of the stock were exchanged, compared to its average volume of 970,465. The business has a fifty day moving average price of $244.99 and a 200 day moving average price of $235.32. The firm has a market capitalization of $37.39 billion, a PE ratio of 28.10, a PEG ratio of 1.76 and a beta of 0.78. ResMed Inc. has a 1-year low of $186.22 and a 1-year high of $263.05. The company has a current ratio of 3.41, a quick ratio of 2.49 and a debt-to-equity ratio of 0.12.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.36 by $0.01. ResMed had a return on equity of 25.67% and a net margin of 26.15%. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the company earned $2.13 earnings per share. ResMed's revenue was up 7.9% compared to the same quarter last year. Research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th were paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date of this dividend was Thursday, May 8th. ResMed's dividend payout ratio is presently 23.79%.

Insider Buying and Selling at ResMed

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $209.85, for a total transaction of $1,680,688.65. Following the transaction, the chief executive officer now owns 455,472 shares of the company's stock, valued at $95,580,799.20. The trade was a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Witte Jan De sold 2,000 shares of ResMed stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $243.47, for a total value of $486,940.00. Following the transaction, the director now directly owns 5,806 shares in the company, valued at approximately $1,413,586.82. This trade represents a 25.62% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,132 shares of company stock valued at $7,075,837. 0.71% of the stock is currently owned by corporate insiders.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.